Personalis to Highlight Breadth of NeXT Personal® Ultra-Sensitive ctDNA Data at ASCO 2026 Annual Meeting, Including Podium Presentation from TRACERx Consortium
Abstracts span six cancer types, including new data on single-digit parts-per-million ctDNA detection
Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for precision oncology, today announced that six clinical abstracts demonstrating the broad use of its NeXT Personal® test will be presented at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting, taking place May 29 to June 2 in Chicago.
Highlights include an oral podium presentation from the landmark TRACERx study, which demonstrates the clinical impact of NeXT Personal’s single-digit parts-per-million (ppm) sensitivity in early-stage non-small cell lung cancer (NSCLC). By detecting circulating tumor DNA (ctDNA) at these ultra-low thresholds, NeXT Personal continues to set new benchmarks for MRD test performance.
“At ASCO, our collaborators will present data that underscores the critical importance of ultrasensitive MRD testing across six distinct solid tumor types, including exceptional new data in colorectal and lung cancer,” said Richard Chen, MD, President and Chief Medical Officer of Personalis. “This data builds upon foundational evidence from our landmark publications in breast cancer, lung cancer, and immunotherapy monitoring, confirming that the ultrasensitive detection provided by NeXT Personal enables early identification of recurrence and precise assessments of therapy response.”
